Category Archives: Byetta Cancer

Featured Stories

Failing DePuy ASR Hip Implants Sending Hundreds of Australians Back to the OR

Roughly 1,000 people in Australia have had to undergo revision surgeries because of failed DePuy ASR hip implants. According to TheAge.com, DePuy Orthopaedics has heard from more than 4,000 people in Australia and New Zealand seeking help with the recalled metal-on-metal hip replacement devices.

Read More

New York Property Owners Challenge Binghamton Fracking Ban

According to a Reuters report, the landowners believe the Binghamton, N.Y., city council and Mayor acted against proper protocol when voting to ban fracking drilling the the city. Instead, they feel the city should have consulted with the Broome County Planning Commission before approving the ban.

Read More

Actos Bladder Cancer Lawsuit Filed by West Virginia Resident

Actos (pioglitazone) continues to be named in lawsuits alleging long-term use of the type 2 diabetes drug caused patients to develop bladder cancer. Just last week, the national law firm of Parker Waichman LLP filed suit against Takeda Pharmaceuticals on behalf of a West Virginia man who developed bladder cancer ...

Read More

Fracking Releasing Hazardous Chemicals into Local Waterways

Fracking Releasing Hazardous Chemicals into Local Waterways

Study shows two hazardous chemicals—ammonium & iodide—are being released & spilled into Pennsylvania and W.Virginia waterways from fracking operations in Marcellus shale.

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

1,000+ Australians Join DePuy ASR Hip Implant Class Action Lawsuit

A class action lawsuit filed in Australia over DePuy Orthopaedics’ recalled metal-on-metal ASR Hip Implants has signed up more than 1,000 plaintiffs. The attorneys representing the Australian ASR Hip Implant lawsuit plaintiffs recently told The Courier-Mail that damages in the lawsuit are expected to be worth more than $200 million. One ...

Read More

First Bard Avaulta Transvaginal Mesh Lawsuit Scheduled for February Trial in MDL

The first test trials in the federal C.R. Bard Avaulta transvaginal mesh litigation will most likely start next year, according to a report from Bloomberg News. About 600 lawsuits involving Bard Avaulta transvaginal mesh products are currently pending in the multidistrict litigation underway Charleston, West Virginia. U.S. District Judge Joseph ...

Read More

Study Finds Metal-on-Metal Hip Implants Associated with High Incidence of Pseudotumors

Yet another study is adding to concerns about the potential dangers associated with metal-on-metal hip implants. The study, published in the Journal of Bone and Joint Surgery, found that large diameter metal-on-metal total hip replacement may be associated with a substantially higher incidence of pseudotumor formation.

Read More

Actos Bladder Cancer Lawsuits Continue, New Complaint Filed by Tennessee Resident

Actos bladder cancer lawsuits continue, with a new complaint filed by a resident of Tennessee. The national law firm, Parker Waichman LLP, represents the Tennessee man who alleges that Actos caused his bladder cancer.

Read More

Study Finds Plavix May Only Benefit Smokers

An emerging study finds that blood thinner Plavix may only benefit smokers. Plavix (clopidogrel) is prescribed for the prevention of blood clots and heart attacks, and has been linked to serious side effects, including the heart attacks and strokes it is supposed to prevent, gastrointestinal and cerebral bleeding, bleeding ulcers, ...

Read More

Diabetes Drug-Pancreatitis Link Supported in Another Study

mimetic-diabtes-linked-to-pancreatitis

Another study has made a connection between Type 2 diabetes drugs known as incretin mimetics and increased rates of developing pancreatitis, a known precursor to pancreatic cancer. Incretin mimetics, are GLP-1-based diabetes therapies and include Byetta and Bydureon (exenatide); Victoza … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Former Pacific Grove Mayor’s Husband Sues Over Wife’s Pancreatic Cancer, Byetta Blamed

byetta_pancreatic_cancer_lawsuit

The husband of former Pacific Grove, Washington Mayor, Sandy Koffman just filed a wrongful death civil lawsuit against two drug companies following his wife’s death from pancreatic cancer last year. His wife had been taking Type 2 diabetes drug, Byetta. … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Gum Disease Tied to Increased Diabetes Risk, May Lead to Increased Risks Tied to Some Type 2 Diabetes Drugs

gum_disease_linked_to_diseases

The links between dental disease and other diseases have been growing, for instance dental disease has been tied to increased risks for developing diabetes and heart disease; pregnancy complications; and, potentially, dementia. Type 2 diabetes is typically treated with any … Continue reading

Posted in Actos, Byetta Cancer, Pharmaceuticals |

Despite Increasing Injury Reports, Mounting Lawsuits, and Growing Data, FDA, EMA Will Not Confirm Increased Pancreatic Side Effects with Incretin Drugs

increting_drugs_side_effects

The U.S. Food and Drug Administration (FDA) agrees with the European Medicines Agency (EMA) that prevailing data concerning Type 2 diabetes medications in the class known as glucagonlike peptide-1 (GLP-1)-based diabetes therapies, do not confirm increased pancreatic side effect risks, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Many Popular Medications Contain Cancer-Causing Compounds, May Increase Cancer Risks

medications_cancer_risks

Cancer is devastating, killing about 600,000 people every year. Cancer is, in fact, the second-leading cause of death in the United States. Yet, despite consumers’ proactive measures to avoid cancer-causing products, some pharmaceuticals might contain carcinogens, ameliorating the best consumer … Continue reading

Posted in Actos, Byetta Cancer, Pharmaceuticals |

Type 2 Diabetes Medication Risks Examined in Journal Review

type2_diabetes_drugs

Incretin mimetics, a class of Type 2 diabetes drugs, are sparking debate and renewing concerns about health risks, especially to the pancreas. In fact, a piece published in the journal BMJ, states that the drugs, which include Byetta and Januvia, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Some Popular Diabetes Medications May Require Additional Review Over Potential Links to Pancreatic Cancer

Diabetes_Medications_Pancreatic_Cancer_Risk

Type 2 diabetes medications in the class known as incretin mimetics, such as Januvia and Byetta, are under increased scrutiny over recent studies discussing the drugs’ links to pancreatitis and potential increased risks to pancreatic cancer. The makers of these … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Januvia, Byetta, Other Diabetes Drugs Focus of Controversy

Januvia_Diabetes

Some popular and money making diabetes drugs are at the center of a conflict over disturbing research findings. Although Dr. Peter C. Butler declined to test its then-new diabetes medication, Januvia, he ultimately relented and, in 2008, observed that the … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Report: Diabetes Drugs Associated with Elevated Cancer Risks

A number of diabetes medications, including Byetta and Januvia, are being probed by the U.S. Food and Drug Administration (FDA) over links to pancreatic cancer. Diabetes drugs manufactured by Merck & Company Inc., AstraZeneca PLC, and other drug makers are … Continue reading

Posted in Allentown Natural Gas Explosion, Byetta Cancer, Pharmaceuticals |

Following U.S. Study, European Union Investigating Diabetes Drugs

Following news in the United States about a recent study that found that Type 2 diabetes drugs, such as Januvia and Byetta, might place patients at increased risk for pancreatic damage, including pancreatic cell growth that could lead to cancer, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.